138 related articles for article (PubMed ID: 6177950)
1. Biochemical studies on the mechanism of cardiotonic activity of MDL 17,043.
Kariya T; Wille LJ; Dage RC
J Cardiovasc Pharmacol; 1982; 4(3):509-14. PubMed ID: 6177950
[TBL] [Abstract][Full Text] [Related]
2. Studies on the mechanism of the cardiotonic activity of MDL 19205: effects on several biochemical systems.
Kariya T; Wille LJ; Dage RC
J Cardiovasc Pharmacol; 1984; 6(1):50-5. PubMed ID: 6199611
[TBL] [Abstract][Full Text] [Related]
3. Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism.
Ahn HS; Eardley D; Watkins R; Prioli N
Biochem Pharmacol; 1986 Apr; 35(7):1113-21. PubMed ID: 2421728
[TBL] [Abstract][Full Text] [Related]
4. Biochemical mechanisms for the inotropic effect of the cardiotonic drug milrinone.
Earl CQ; Linden J; Weglicki WB
J Cardiovasc Pharmacol; 1986; 8(4):864-72. PubMed ID: 2427830
[TBL] [Abstract][Full Text] [Related]
5. Studies aimed at elucidating the mechanism of action of CI-914, a new cardiotonic agent.
Weishaar RE; Quade M; Schenden JA; Boyd DK; Evans DB
Eur J Pharmacol; 1985 Dec; 119(3):205-15. PubMed ID: 3004993
[TBL] [Abstract][Full Text] [Related]
6. Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue.
Price B; Pyne NJ; Houslay MD
Biochem Pharmacol; 1987 Dec; 36(23):4047-54. PubMed ID: 2825712
[TBL] [Abstract][Full Text] [Related]
7. Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle.
Endoh M; Yanagisawa T; Taira N; Blinks JR
Circulation; 1986 Mar; 73(3 Pt 2):III117-33. PubMed ID: 2417745
[TBL] [Abstract][Full Text] [Related]
8. Differential inhibition of cardiac cyclic nucleotide phosphodiesterase isozymes by cardiotonic drugs.
Harrison SA; Chang ML; Beavo JA
Circulation; 1986 Mar; 73(3 Pt 2):III109-16. PubMed ID: 3002661
[TBL] [Abstract][Full Text] [Related]
9. New milrinone analogues: in vitro study of structure-activity relationships for positive inotropic effect, antagonism towards endogenous adenosine, and inhibition of cardiac type III phosphodiesterase.
Floreani M; Fossa P; Gessi S; Mosti L; Borea PA; Dorigo P
Naunyn Schmiedebergs Arch Pharmacol; 2003 Feb; 367(2):109-18. PubMed ID: 12595951
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds.
de Cheffoy de Courcelles D; de Loore K; Freyne E; Janssen PA
J Pharmacol Exp Ther; 1992 Oct; 263(1):6-14. PubMed ID: 1328613
[TBL] [Abstract][Full Text] [Related]
11. Cyclic nucleotide phosphodiesterases from frog atrial fibers: isolation and drug sensitivities.
Lugnier C; Gauthier C; Le Bec A; Soustre H
Am J Physiol; 1992 Mar; 262(3 Pt 2):H654-60. PubMed ID: 1373036
[TBL] [Abstract][Full Text] [Related]
12. In vitro characterization of the effects of MCI-154, a novel cardiotonic agent, on cardiac tissues.
Narimatsu A; Kitada Y; Satoh N; Morita M; Muroyama A; Kobayashi M; Ohizumi Y
Jpn J Pharmacol; 1989 Mar; 49(3):397-405. PubMed ID: 2545964
[TBL] [Abstract][Full Text] [Related]
13. Competitive inhibition of phosphodiesterase activity by amrinone: its implication in the cardiac effect of the drug.
Carpenedo F; Floreani M; Cargnelli G
Pharmacol Res Commun; 1984 Oct; 16(10):969-77. PubMed ID: 6095329
[TBL] [Abstract][Full Text] [Related]
14. Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle.
Endoh M; Yamashita S; Taira N
J Pharmacol Exp Ther; 1982 Jun; 221(3):775-83. PubMed ID: 6283063
[TBL] [Abstract][Full Text] [Related]
15. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents.
Weishaar RE; Burrows SD; Kobylarz DC; Quade MM; Evans DB
Biochem Pharmacol; 1986 Mar; 35(5):787-800. PubMed ID: 3006691
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships of milrinone analogues determined in vitro in a rabbit heart membrane Ca(2+)-ATPase model.
Cody V; Wojtczak A; Davis FB; Davis PJ; Blas SD
J Med Chem; 1995 May; 38(11):1990-7. PubMed ID: 7783130
[TBL] [Abstract][Full Text] [Related]
17. The two mechanisms of action of racemic cardiotonic EMD 53998, calcium sensitization and phosphodiesterase inhibition, reside in different enantiomers.
Lues I; Beier N; Jonas R; Klockow M; Haeusler G
J Cardiovasc Pharmacol; 1993 Jun; 21(6):883-92. PubMed ID: 7687712
[TBL] [Abstract][Full Text] [Related]
18. Characterization of indolidan- and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions.
Lugnier C; Muller B; Le Bec A; Beaudry C; Rousseau E
J Pharmacol Exp Ther; 1993 Jun; 265(3):1142-51. PubMed ID: 8389853
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo studies of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), a novel positive inotropic drug, in various animals.
Yamashita S; Hosokawa T; Kojima M; Mori T; Yabuuchi Y
Arzneimittelforschung; 1984; 34(3A):342-6. PubMed ID: 6331464
[TBL] [Abstract][Full Text] [Related]
20. Role of ischemia-reperfusion on myocardial cyclic AMP and cyclic AMP phosphodiesterase: effects of amrinone on regional myocardial force and shortening.
Tse J; Cimini C; Kedem J; Rodriquez E; Gonzalez M; Weiss HR
J Cardiothorac Vasc Anesth; 1993 Oct; 7(5):566-72. PubMed ID: 8268438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
